Physician profile
Michael D Friedman
NPI 1831164235
$1,824.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $602 · 2021: $456.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $389.20 | 2019-2021 | |
| Astellas Pharma US INC | $248.22 | 2019-2021 | |
| Janssen Biotech, INC. | $203.44 | 2019 | |
| Boston Scientific Corporation | $154.52 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $150.75 | 2020-2021 | |
| Procept Biorobotics Corporation | $140.58 | 2019 | |
| Coloplast Corp | $123.60 | 2019-2021 | |
| Neotract INC. | $73.08 | 2019-2020 | |
| Allergan, INC. | $67.02 | 2019-2021 | |
| Antares Pharma, INC. | $55.25 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $52.70 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.09 | 2020 | |
| Photocure INC | $24.93 | 2020 | |
| Karl Storz Endoscopy-America | $21.63 | 2020 | |
| Pfizer INC. | $17.60 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $16.42 | 2020 | |
| Teleflex LLC | $16.33 | 2021 | |
| Myovant Sciences INC. | $15.99 | 2021 | |
| Dentsply Ih INC. | $11.76 | 2019 | |
| Olympus America INC. | $11.53 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.